Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Question for Phantom or AntiMarv or anybody. If I remember correctly, the AML trial (MT-401) was given as a "stand alone" treatment, and it was compared to conventional "standard of care", so they can say ... look MT-401 did SO MUCH better than conventional "standard of care".

But with this for Pancreatic it is: "The Company intends to initiate a Phase 1 multicenter study of MT-601 administered in combination with front-line chemotherapy to patients".

So question is why not "stand alone"? Why in combination with front-line chemotherapy?

I thought one of the purposes of "modern" drugs was to get away from chemo.
And now I guess the results will be determined by ... look MT-601 did SO MUCH better than Chemotherapy alone??? Is that correct?

Thanks